Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants.
The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining.
The analysis, published in the International Forum of Allergy & Rhinology, demonstrated that Intersect ENT’s products significantly improved endoscopic outcomes of frontal sinus surgery compared to surgery alone.
Use of the company’s implants resulted in a 46.8% relative reduction in the need for postoperative interventions after 30 days. Intersect ENT also reported a significant reduction in postoperative interventions after 90 days.
There were no implant-related adverse events in the 160-patient group.
“Frontal sinus surgery in patients with chronic rhinosinusitis has historically been associated with poorer outcomes than that of the other paranasal sinuses,” lead author Dr. Ameet Singh said in prepared remarks. “This analysis provides important insights into outcomes in various patient subgroups and also demonstrates that Propel implants improve the outcomes of frontal sinus surgery by reducing the need for post-operative interventions through 90 days.”
“We are very pleased to see the positive findings of this study added to the robust pool of clinical evidence supporting our steroid releasing implants,” president & CEO Lisa Earnhardt added. “We’re delighted that the Propel family of implants continues to be a strong, evidence-based option for ENTs seeking improved outcomes for patients following sinus surgery.”
Also this month, Intersect ENT topped expectations on Wall Street with its third-quarter financial results.
